1. Home
  2. AGIO vs ETV Comparison

AGIO vs ETV Comparison

Compare AGIO & ETV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.39

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

ETV

Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

HOLD

Current Price

$14.20

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
ETV
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
AGIO
ETV
Price
$27.39
$14.20
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$32.13
N/A
AVG Volume (30 Days)
2.7M
252.5K
Earning Date
10-30-2025
01-01-0001
Dividend Yield
N/A
8.75%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,791,000.00
N/A
Revenue This Year
$28.75
N/A
Revenue Next Year
$139.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.26
N/A
52 Week Low
$22.24
$11.05
52 Week High
$46.00
$13.50

Technical Indicators

Market Signals
Indicator
AGIO
ETV
Relative Strength Index (RSI) 37.05 46.95
Support Level $26.80 $14.20
Resistance Level $28.61 $14.45
Average True Range (ATR) 1.19 0.17
MACD 0.25 0.00
Stochastic Oscillator 56.00 39.20

Price Performance

Historical Comparison
AGIO
ETV

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.

Share on Social Networks: